Inactive Instrument

Teligent

Equities

TLGT

US87960W2035

Teligent, Inc Provides Earnings Guidance for the Three Months Ending September 30, 2020 and December 31, 2020

August 19, 2020 at 05:02 pm IST

Teligent, Inc. provided earnings guidance for the three months ending September 30, 2020 and full year ending December 31, 2020. For the three months ending September 30, 2020, the company is forecasting revenue of approximately $13.5 million and an operating loss of approximately $3.9 million. For the three months ending December 31, 2020, the company is forecasting revenue of approximately $15.5 million and an operating loss of approximately $3.1 million.

Latest news about Teligent

Teligent, Inc. Went Out of Business	26/22/26	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	15/22/15	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	25/22/25	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	24/22/24	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	29/22/29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	27/22/27	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	08/22/08	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	01/22/01	CI
Motion for Case Conversion Filed by Teligent, Inc.	23/22/23	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	10/22/10	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	03/22/03	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	03/22/03	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	03/22/03	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/22/19	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/22/19	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/22/19	CI
London Shares to Open Higher as Traders Focus On Key Data	17/22/17	DJ
Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition	17/22/17	MT
Asset Purchase Agreement Filed by Teligent, Inc.	17/22/17	CI
Asset Purchase Agreement Filed by Teligent, Inc.	17/22/17	CI
Asset Purchase Agreement Filed by Teligent, Inc.	17/22/17	CI
Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.	17/22/17	CI
Notice of Selection of Successful Filed for Teligent, Inc.	14/22/14	CI
Notice of Selection of Successful Filed for Teligent, Inc.	14/22/14	CI
Notice of Selection of Successful Filed for Teligent, Inc.	14/22/14	CI

Chart Teligent

Duration

Period

More charts

Company Profile

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company